Delaware | 001-37797 | 27-3948465 | ||
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) |
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Common Stock $0.0001 Par Value | INNT | The Nasdaq Stock Market LLC |
Item 2.02. | Results of Operations and Financial Condition. |
Item 9.01. | Financial Statements and Exhibits. |
Exhibit No. | Description |
Exhibit 99.1 |
Innovate Biopharmaceuticals, Inc. | |||
Date: August 8, 2019 | By: | /s/ Edward J. Sitar | |
Edward J. Sitar | |||
Chief Financial Officer |
• | The screening and monitoring of patients in the first Phase 3 celiac disease trial continues |
• | Company has secured an initial set of 17 active clinical testing sites |
• | Research collaboration with Institut Gustave Roussy continues to study regulation of intestinal permeability and the gut microbiota using larazotide in immuno-oncology checkpoint inhibitor failure preclinical models |
• | Data analysis from pre-clinical models in NASH advances from studying larazotide in both ex vivo and animal models |
• | Progression of research collaboration with Dr. Jay Luther and Dr. Raymond Chung at the Gastroenterology Division at Massachusetts General Hospital to research the effects of larazotide on certain forms of alcoholic liver disease, such as ASH |
• | Presented 3 posters at DDW 2019 in May |
• | Acceptance of poster at 2019 World Congress of Gastroenterology in September |
(3'I&7&X_AUIZB=AMM96MDI6UMX80>HC0+G\JGJ*6Z@@=4FF MCC9_NAW )^E2TAA137D2-"TC*JCJ6. *CAO+:X.(+B*0^B.#_*@"1T66-DD4 M,C## C@BLO\ X1;1/^@5:?\ ?H5K5!+>VL$@CFN88W/17D /Y4 %G96VGP>3 M9P1P19)V1K@9J>D!R,CI44EW;PR".6>)';HK. 3^% $DD:31M'(H9'!5E(X( M/45F'POHAQ_Q*K3C_ID*U:@^VVOVC[/]IA\[IY>\;ORZT .M[>&T@2"WC6*) M!A408 J6H)[VVMG5+BYAB9N@=PI/YT7=W#96SSW$B1QJ,Y9@ ?:@"D?#.BLQ M8Z7:%BTACVB)3+\ M[L?K_2M/QB;T^'Y4TR[CM;IV 5GE$9([@,>AJFFM&2FGJC=JG?Z38ZHJ"_M8 MK@1DE1(N<9JKX8AOH/#]JFIW*W-SMRT@;=D9X^;OQWK2FN(K=-\\J1K_ 'G8 M ?K2:LQIW1GV_AK1[2X2>WTVVCFC.4=4 *FM2HX9XKA-\,B2(?XD8$?I2R2) M$A>1U11U+' I#'U1O]%T[5)$>^LH;AT&%,BY(%6(;NWN?]1/%+C^XX;^5<_\ M0KUK+P==E&97E*Q*5.",F@"]_P (CH/_ $";3_OV*/\ A$=!_P"@3:?]^Q69 M\-H9(_",4LSN[SR/)EV).,X'7Z5TLUW;VQ GGBB)Z;W"Y_.JE=.Q,;-7*UCH M>F:9,TMC8P02,NTM&N"1Z5?IJLKJ&5@RGH0<@TZI*"BBB@ HHHH **** "LK MQ)HYUW0Y[)7"2-AD8] P.16K10G8'J>!:CI]WI-VUM?0/#*/4<-[@]Q4FCZU M=:'?K=V;+O VLK#(9>X->VZGI5GK%J;>_@6:,],]5/J#V->8^(_AY>Z7ON-, MW7EJ.=@&94'T[_A71&HI:,PE!QU1VWASQMI^O!8F(MKS_GBY^]_NGO\ SK0U MKP]8:]!Y=[""X'R2KPZ?0_TKP?=@^A!_(UV?AOXCW>F[+?5 UW:C@2?\M$'_ M +-^-3*G;6(XU$])%7Q%X+U#02TJ W5F/^6J#E1_M#M]>E<[%.\,BRPR,CJ< MJZG!!]C7O.G:G9:Q:">RG2>)NN.WL1VKE_$GPZM-2WW&EE;2Z/)3'[M_P['Z M4XU>D@E3ZQ,GP_\ $MX4$&MHTB@<7$8^;_@0[_45/KGQ.C,/EZ)$WF,.9IEQ MM^B]S7 ZGIMYH]T;?4('AD[;NC#U![BHK.TN-1NEM[.%YIFZ(@R?_K"JY([D M\\MB6ZO9[ZX>XNIGEE?J[G)K5T#PKJ/B%@UNGE6P/S3R#"_AZUU_AOX;16VV MYULK/+U%NI^1?J>_\J[2YNK32K(RW$D5M;1#&3\J@>@_PJ95>D2HT^LC.T'P MIIV@1@P1^9 098_3T'TINO\ BW3?#Z%;B3S+G&5@CY8_7T'UKC/$GQ+E MN"UOH8,,70W##YF_W1V^IK@Y)GD=I)79W8Y9F.23[FDJ;>LANHEI$V?$'B2Z M\17BS705$C!$<:=%!]^YJA:6T]_!-0UP)//FTLS_& MX^9Q_LC^IKU+1]!T_0K?RK"!4)'S2'EW^IJG-1T1*@Y:LH^#?#\GA_1S% , ?@*Z"BBL&[NYLE96"LOQ-=_8?#.HW&<%8& /N1@?SK4KE/B0 MTY\)2PV\4DC32(I"*6.,Y/3Z4M]!WMJ<)X0A\4VVF7-WX>AB:&1MKE@I8E1_ M"#]:U_AJ;*]UV[N;YIY-:&YLRXVXSAB/?M53PYXNU'1M"33+#0YYIPS'S"K8 M))STQ6U\/_"FH66HSZSJR&&:56"1-][+')8CM]*W>[N<\5HK$?Q>NL:?I]H. M3)(TA'T&!_.NGL'C\.>"8))!\EI:!R/4[ D/4U6L_0\W\.Z+$*^N]1UNZ MF^SQMM6-&P,GG ] !1X7>?PW\19-&MYWEM'D:)E8\'Y<@X]14>@:YK7@N*YT MR719I9)'+1_*W#=.H!R.*W/ WA6_75YM?UM#'<2%C'&WWLMU8CMZ 5IL_*QG MOZW'_%NY":)9VI_Y:S[B/91_]>L.^\$R#P0-7U"^F-U# KQPG&Q$XPOUP:?\ M5)VNO$5C91JSM'%G8.22QZ?I2ZMK>N^,+.+1[#1I[:,%1,6S@X[$D !:F*?+ MIW*DUS:G1?"V]N+KPU)'.[.L$Q2,L &/#R6H;>Z*9)6 ^\W4X_E7$?#.UFN?$VI:C<12H=AP70 MC)=L]_84)IS F?8=:XB6";5OB^KM#)Y,$H^8H=N$7UZ=:Z'XE:/=ZKH$3 M64;2O;R^8T:\EEQC@=\4I.\8W*BK2E8YG2O"TGB'1KGQ!XCO;B0,CO&@;&0, M\^PXX J;X16FZZU&\YVJBQ+^)S_054@U37M1\%2Z7%IS06MK"1- T%\R[ &M6LOL M]Y/<74Z^8TCGYMX/4'W-;GA^"74OBM>7DD,HBB:1E9D(''RCFD\2P2ZO\4K* M#R93#"T2EMAV\?,>>E5'3E1,M>9F=XU\,R:9I5KJFH7\USJ-S(!*'^Z/E)^7 MTQC%>AZ-?M8^![2^U!B3%:"20GJ<#_\ 57*?%4SW=YI=C#%*X^9SM0D9) '] M:ZW7](EN_!UQIEI_K?LX1!G&=N./QQ4MWA\RDK3^1PFC:??_ !'U*XO-5NI8 MK"%L+%&< $]%';IU-5?".F0?\+):&SW_ &:TDD923DD+P,_B:F\(ZCX@TVWN M-$L=*?SY9"?.E4J("1@D\8.,5<^%EE+%KFI23)("L>P,Z$;OFY//TJ]F[;6, M]UKO -]5U:_M;&;1G1?NS7& M& 7 ZX(X_.HC?E]W ]L:/COQ!)X :W,.@?\ M(\;FXU.XNM 6PC:66U _ KE M=*UG[+&D,/@J.6_0!2XB/S'U((/-$-O,)[KL=O\ #UKUO"-L;_?NRWEF3[WE MY^6N0\,*-6^*U[>; GPM)+9HSIY 1C1KBZN9E,>W! SNR&W8QBG%WDV#5HI%SQ?PA<27!;]P0\84X!?H,_G7)>%+&^N/B7-/J2,9HC))(X4[-W3 /H,_I76? M$>SN[WPH\=G$\K+*CNB#)VCVI2T44..KDSGOAYX/LKZQM]:N_,-Q'<%H@&PN M%Z9'US2?%RX\VXTRQ49.&DQ[G"BM?X9:A=SZ0UC/9&"&S&%E8$&0DDG@BL/Q M+!+J_P 4K2#RI3#$\2%MAV\?,>>E4]:B3V)6E-M;G<7U['X7\)><5#"TMU55 M_O-@ #\ZX#P_X:O/'SSZIK5],(-Y153N>X / KO_%VCRZYX;NK.W(\Y@&C! M. 6!SBO/?#OB;6O"EJ^E2:)-.P % M[@Q-(\, :4ER-S$]!Q^ KBM!T:]^(5U<:EK=Y,MG&^U(XS@9ZX'8 #'/4UV7 MB>QO->\$RQ11%+N6))/)[Y&"5KB/"VI>((-)GT*QTQT8LQ:YE5E\@$ 3&VW?9K02%,GMG:,_G6W\7;O;IUA:*>9)6D(^@P/Y MU!\)K1XKC4Y9(Y$.$0%T*Y')[U!X^BFU;QUIUDD4K1H(T+!"5^9LGGZ535YQ M1*=H29W.DVTNF^$+:&W3,T5H-BGNVW/\Z\GT)-)UC5+A?%EW=) U"XTC1I;FRLWNYDP%A0'GGGIV KS#Q!<7/C6YMUT_PY-;W@.)92 MN-WU.!Q[FIB[R;')6BD>JZ/IL&D:5;V5JS-%$N%9CDMWS5VJ>D6;Z?I%I:2O MODAB5&;U(%7*B6[-([(****0PHHHH **** "BBB@ HHHH Y?Q)X$T_7@TT0% MI>XXE0<,?]H=_P"=>5:YX>U'P]<>7?PD(3A)5Y1_H?Z5[[4-S:P7MN\%U$DL M3C#(XR#5QFT1*"9X!INJWFCW8N;"=H91UQT8>A'<5Z?X:^)%GJ96VU4)9W1X M#Y_=O^/8_6L?Q+\,7BWW.@L73J;5SR/]T]_H:\]FBD@E>*9&CD0X9'&"#[BM M?=F97E ^B;FSM;^'9=013QD='4,*;9Z=9Z HJ?5OB!KFK1O$9TMH7&"D"[ /]*\KUG7]0UZX\[4)R^/NQKPB?05F*"S!5!+,< 9)-= MUX9^&EU?%;C6MUK;]1"#^\?Z_P!W^=6E&!# U>I>&OAW9:1LN-0VWEX.1D?NT/L._U-=/I^FVFE6BVUC D,*_PJ.ON3W-6 MJB51LTC32W$Z4M%%9F@4444 %%%% !1110 4444 %%%% ' W/A;5;[XDIJT\ M"BPCD5E?S%)PJ\<=>M=]113;NDA)6;84444AA1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 5BZ_X4TSQ$G^FPXG PL\?#K^/< M>QK:HH3L#5SR:_\ A1JD,C&QNK>XCS\N\E&Q[]14=G\*M8F